Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Calderasib · MK-1084

Small molecule · Inhibitor of KRAS G12C (KRAS) · developed by Merck &

Phase 3 Most advanced trial

MRK Developer

2 Registered trials

What is Calderasib?

Calderasib is an orally available small-molecule inhibitor of KRAS G12C mutations. It selectively targets KRAS G12C-mediated signaling to halt proliferation and metastasis in susceptible tumor cells. It is studied in colorectal and lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-1084
Drug type: Small molecule
Targets: KRAS G12C (KRAS)
Mechanism: Inhibitor of KRAS G12C (KRAS)
Pathways: KRAS signaling, cell proliferation, metastasis
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: YQF4ART47C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06997497	Phase 3	Colon Adenocarcinoma	Recruiting	MRK
NCT07286149	Phase 1/2	Lung Neoplasm Malignant	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colon AdenocarcinomaLung Neoplasm MalignantRectal Adenocarcinoma

Other drugs acting on KRAS

Sotorasib FDA approved AN9025 Phase 1 ARV-806 Phase 1/2 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Favezelimab Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Calderasib

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z